ReviewBMC medicine2020
Insulin: too much of a good thing is bad.
Review in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 3 syntheses or guidelines pooled it, 239 citations in OpenAlex.
- Effects of energy-matched low- versus high-carbohydrate diets on glycaemic control, lipid profile, and body composition in healthy adults: a systematic review and meta-analysis of randomised controlled trials.European journal of nutrition · 2026Pooled it
- Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence.Annals of medicine · 2024Pooled it
- Insulin Treatment May Increase Adverse Outcomes in Patients With COVID-19 and Diabetes: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Trial
- Impact of a mineral enriched, fiber complex on glycaemic response and satiation in healthy adults: a double-blind, crossover intervention study.European journal of nutrition · 2025Trial
- Progressive Weight Loss-Induced Remission of Insulin Resistance/Hyperinsulinemia and Improvements in Cardiovascular Risk Factors.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Trial
- Impact of a Low-Insulin-Stimulating Bread on Weight Development-A Real Life Randomised Controlled Trial.Nutrients · 2023Trial
- Postprandial Responses to a Standardised Meal in Hypertension: The Mediatory Role of Visceral Fat Mass.Nutrients · 2022Trial
- A High-Protein and Low-Glycemic Formula Diet Improves Blood Pressure and Other Hemodynamic Parameters in High-Risk Individuals.Nutrients · 2022Trial
- Trial
- High-Protein, Low-Glycaemic Meal Replacement Decreases Fasting Insulin and Inflammation Markers-A 12-Month Subanalysis of the ACOORH Trial.Nutrients · 2021Trial
- Trial
- Interrelationships between Refined Carbohydrates, Periodontal Diseases, and Cognitive Decline: A Narrative Review.Advances in nutrition (Bethesda, Md.) · 2026Review
- Association of various insulin resistance surrogate markers with mortality risk in critically ill patients with ischemic stroke: a retrospective cohort study.Cardiovascular diabetology · 2026Article
- Why hyperinsulinemia is detrimental to weight loss: insights from type 1 diabetes.BMC medicine · 2026Review
- Interplay between obesity-associated insulin resistance and immune system through the lens of evolutionary medicine.Molecular metabolism · 2026Review
- Exposure to phthalate and phenol mixtures and obesity in children and adolescents: the dominant role of bisphenol A.Lipids in health and disease · 2026Article
- Low-Carbohydrate (Ketogenic) Diet in Children with Obesity: Part 2-Hormonal Effects of the Ketogenic Diet.Children (Basel, Switzerland) · 2026Article
- Association of HindIII Polymorphism of the Lipoprotein Lipase (LPL) Gene (rs320) and Plasma Metabolic Parameters in a Nigerian Population.Biochemical genetics · 2026Article
- Insulin Signaling in Alzheimer's Disease: Association with Brain Insulin Resistance.International journal of molecular sciences · 2026Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin shares a limited physiological concentration range with other endocrine hormones. Not only too low, but also too high systemic insulin levels are detrimental for body functions. MAIN BODY: The physiological function and clinical relevance of insulin are usually seen in association with its role in maintaining glucose homeostasis. However, insulin is an anabolic hormone which stimulates a large number of cellular responses. Not only too low, but also excess insulin concentrations are detrimental to the physiological balance. Although the glucoregulatory activity of insulin is mitigated during hyperinsulinemia by dampening the efficiency of insulin signaling ("insulin resistance"), this is not the case for most other hormonal actions of insulin, including the promotion of protein synthesis, de novo lipogenesis, and cell proliferation; the inhibition of lipolysis, of autophagy-dependent cellular turnover, and of nuclear factor E2-related factor-2 (Nrf2)-dependent antioxidative; and other defense mechanisms. Hence, there is no general insulin resistance but selective impairment of insulin signaling which causes less glucose uptake from the blood and reduced activation of endothelial NO synthase (eNOS). Because of the largely unrestricted insulin signaling, hyperinsulinemia increases the risk of obesity, type 2 diabetes, and cardiovascular disease and decreases health span and life expectancy. In epidemiological studies, high-dose insulin therapy is associated with an increased risk of cardiovascular disease. Randomized controlled trials of insulin treatment did not observe any effect on disease risk, but these trials only studied low insulin doses up to 40 IU/day. Proof for a causal link between elevated insulin levels and cardiovascular disease risk comes from Mendelian randomization studies comparing individuals with genetically controlled low or high insulin production.
conclusionsThe detrimental actions of prolonged high insulin concentrations, seen also in cell culture, argue in favor of a lifestyle that limits circadian insulin levels. The health risks associated with hyperinsulinemia may have implications for treatment regimens used in type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.